The stock traded Friday morning at $56.15. This remains a solid pharmaceutical stock to own. Bristol-Myers Squibb Co. (NYSE: BMY) is a global pharmaceutical company focused on discovering, developing, licensing and marketing …
Loncar runs several biotech stock indexes including the Cancer Immunotherapy …
Amazon stock will benefit from strong growth in the Prime subscription ... BioMarin Provides Update on Phase II Talazoparib Study - Analyst Blog by Zacks on Jul 21, 2015 Bristol-Myers' Opdivo Study Stopped Early, Meets Endpoint …
especially Editor’s Portfolio holding Bristol-Myers Squibb (BMY), suggests Chuck Carlson, dividend reinvestment specialist and editor of DRIP Investor. The stock is down 25% since mid-February and is trading around its lowest level in a year. …
"We were wrong," H.C. Wainwright's Debjit Chattopadhyay acknowledged in a target price revision, lowering his 12-month target on the stock to $19 from $33 and ...
State Of Tennessee Treasury Department reported 0.41% of its portfolio in Bloomsbury Publishing plc (LON:BMY). San Francisco Sentry Group (Ca) invested in 15,733 shares or 0.28% of the stock. Paragon Capital Ltd Liability Corporation …